Skip to main content

Table 1 Characteristics of healthy controls and enrolled HIV-1 infected cART-naive or long-term cART-treated patients in flow cytometry phenotyping

From: Activation-induced pyroptosis contributes to the loss of MAIT cells in chronic HIV-1 infected patients

Characteristic HCs (n = 33) ECs (n = 15) TPs CRs (n = 28) INRs (n = 15)
CD4 ≥ 350
(n = 28)
CD4 < 350
(n = 41)
Age [years, M (Q1, Q3)] 29.0 (27.0, 35.5) 35.0 (29.0, 43.0) 28.5 (22.0, 40.0) 34.0 (27.0, 37.5) 25.0 (22.5, 31.5) 30.0 (24.8, 25.3)
Gender [male, n(%)] 18 (54.5) 12 (80.0) 23 (82.1) 33 (80.4) 26 (92.9) 14 (93.3)
CD4+ T cell counts [cells/µl, M (Q1, Q3)] 822.0 (684.0, 981.5) 627.0 (458.0, 741.0) 421.0 (374.3, 596.8) 194.0 (134.0, 277.5) 575.0 (506.5, 725.5) 155.0 (137.5, 178.0)
CD8+ T cell counts [cells/µl, M (Q1, Q3)] 621.0 (512.5, 765.0) 1026.0 (822.0, 1276.0) 1267.0 (1008.0, 1757.0) 1061.0 (676.0, 1335.0) 714.0 (558.5, 826.0) 694.5 (353.5, 893.5)
Plasma viral loads [× 104 copies/ml, M (Q1, Q3)] NA NA 15.8 (3.8, 56.9) 11.3 (4.2, 46.8)  < LOD  < LOD
cART regimen [n(%)]
 3TC/EFV/TDF NA NA NA NA 25 (89.2) 14 (93.3)
 3TC/LPV/TDF NA NA NA NA 2 (7.1) 1 (6.7)
 3TC/AZT/TDF NA NA NA NA 1 (3.6) 0
 3TC/DTG/TDF NA NA NA NA 0 1 (6.7)
cART duration time [month, M (Q1, Q3)] NA NA NA NA 42.9 (34.9, 65.8) 46.2 (35.4, 90.3)
  1. HIV human immunodeficiency virus, HCs healthy controls, ECs elite controllers, TPs treatment-naive patients, CRs complete responders, INRs immunological non-responders, NA not applicable, cART combined antiretroviral therapy, 3TC lamivudine, EFV efavirenz, TDF tenofovirdisoproxil, LPV lopinavir, AZT azidothymidine, DTG dolutegravir, < LOD below the limit of detection of 80 copies/ml